Login to Your Account

Incyte Buying Maxia For $28.3M; Plans Staff, Expense Reductions

By Brady Huggett

Wednesday, November 13, 2002
Incyte Genomics Inc., known for its databases and research solutions, is acquiring Maxia Pharmaceuticals Inc. and its pipeline of early stage drugs for an amount that could reach $42.3 million. Also Tuesday, the company released its third-quarter earnings and said it was reducing staff by 37 percent and planning to seriously reduce expenses. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription